Meds

Escitalopram (Lexapro) Will Remain as the Clinical Gold Standard Treatment For Major Depressive Disorder

Escitalopram (Lexapro) Will Remain as the Clinical Gold Standard Treatment For Major Depressive Disorder

Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources

 

WALTHAM, Mass., July 15, 2008 /PRNewswire via COMTEX/ — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug’s long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists’ prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources
 

 

WALTHAM, Mass., July 15, 2008 /PRNewswire via COMTEX/ — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug’s long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists’ prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

The new report entitled Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market finds that if an agent preventing recurrence of depressive mood episodes superior to that of sales-leading Wyeth’s Effexor XR were to be launched, it would earn a 25 percent patient share, according to surveyed psychiatrists. The report also finds that although Effexor XR is the sales leader in the major depressive disorder drug market, the current and future Decision Resources proprietary clinical gold standard treatment for the indication is escitalopram (Lundbeck’s Cipralex/Seroplex; Forest’s Lexapro).

Although escitalopram’s efficacy is not the highest in our study, the drug outscored any other current therapy in the area of safety. Experts we interviewed explain that because the drug is an active metabolite, lower doses can be used, an advantage that results in safety benefits.

“Based on available data and expert opinion, we do not expect any therapy under development to displace escitalopram as the clinical gold standard for major depressive disorder,” said Carlos Dedesma, Ph.D., analyst at Decision Resources.

“Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with escitalopram.” About the Report Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications.

These outputs are driven by quantitative and qualitative primary research.

DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians’ expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets.

Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

[email protected] SOURCE Decision Resources URL: http://www.decisionresources.com www.prnewswire.com Copyright (C) 2008 PR Newswire. All rights reserved -0- KEYWORD: Massachusetts INDUSTRY KEYWORD: MTC

*Forum Admin Note:

The Lundbeck logo we have on the front page of the Portal is a research-based company.  They engage in research to find new drugs for treatment of CNS disorders, includ­ing depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.

These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.

They have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. They believe that they can make a significant difference, and they are happy to do so in cooperation with others.

Leave a Reply